Vimeo
LinkedIn
Instagram
Share |

Family Business

With the coronavirus health and wealth crisis disrupting traditional investments in a fractured world, the virtues of the decentralised digital cryptocurrency are becoming attractive, but how can family investors get onboard with confidence?

With the coronavirus health and wealth crisis disrupting traditional investments in a fractured world, the virtues of the decentralised digital cryptocurrency are becoming attractive, but how can family investors get onboard with confidence?

Family businesses are overcoming global coronavirus lockdowns by using innovative digital strategies to reassure audiences, update customers, share healthcare advice and pay tribute to their workforce.

Family businesses are overcoming global coronavirus lockdowns by using innovative digital strategies to reassure audiences, update customers, share healthcare advice and pay tribute to their workforce.

Bosch launches rapid Covid-19 test and prepares for global recession, Deichmann manages reputational risk over coronavirus rents, sales-hit Volkswagen reviews all projects as car production resumes.

Bosch launches rapid Covid-19 test and prepares for global recession, Deichmann manages reputational risk over coronavirus rents, sales-hit Volkswagen reviews all projects as car production resumes.

The global impacts of the coronavirus pandemic on financial markets are still being felt, but the investment firm Ruffer has shared the effects on its own portfolio and what could happen next in a new podcast.

Duncan MacInnes, investment director, discusses Covid-19: how it has changed the investment landscape, the impact on the Ruffer portfolio and what could happen next.

The coronavirus pandemic has triggered a race for disruptive innovation in diagnostics, new therapies and novel vaccines, but the global life sciences industry was already expected to reach more than $2 trillion in gross value by 2023, up from $1.6 trillion before the crisis.

The coronavirus pandemic has triggered a race for disruptive innovation in diagnostics, new therapies and novel vaccines, but the global life sciences industry was already expected to reach more than $2 trillion in gross value by 2023, up from $1.6 trillion before the crisis.

Click here >>
Close